难治性高血压的内分泌与血流动力学变化及螺内酯或阿米洛利的降压反应:PATHWAY-2机制亚研究
PATHWAY-2是在英国14个中心314例难治性高血压患者中进行的随机双盲交叉试验,比较安慰剂、螺内酯25-50 mg、比索洛尔5-10 mg与多沙唑嗪4-8 mg各12周对家庭收缩压的影响。三个亚研究分别评估醛固酮/肾素作为降压预测因子及原发性醛固酮增多症患病率、血流动力学指标变化,以及阿米洛利10-20 mg开放标签阶段的降压效果。结果提示难治性高血压常为盐潴留状态,可能与醛固酮不适当分泌有关,螺内酯可克服盐潴留,阿米洛利似乎与螺内酯降压效果相当。
要点
- 螺内酯降低家庭收缩压的幅度可由醛固酮/肾素比值(r2=0·13,p<0·0001)和血浆肾素(r2=0·11,p=0·00024)预测。
- 126例中31例(25%,95%CI 17-33)被认为醛固酮浓度不适当升高。
- 螺内酯使胸腔液体含量较基线降低6·8%(95%CI 4·0-8·8;p<0·0001),其他治疗无此变化。
核心结论
- 结果提示难治性高血压常为盐潴留状态,最可能由醛固酮不适当分泌所致。
- 螺内酯阻断盐皮质激素受体可克服盐潴留及高血压对治疗的抵抗。
- 阿米洛利似乎与螺内酯降压效果相当,为难治性高血压提供了替代治疗选择。
研究设计与样本
- PATHWAY-2为在英国14个初级和二级诊疗中心开展的随机双盲交叉试验,纳入314例难治性高血压患者。
- 患者接受安慰剂、螺内酯25-50 mg、比索洛尔5-10 mg和多沙唑嗪4-8 mg各每日一次治疗12周,主要结局为家庭收缩压变化。
- 三个亚研究分别评估醛固酮、肾素及醛固酮/肾素比值对家庭收缩压的预测及原发性醛固酮增多症患病率(亚研究1);在7个具备血流动力学监测条件的中心评估各药对胸腔液体指数、心脏指数、每搏指数和体循环血管阻力的影响(亚研究2);在可选6-12周开放标签延展期评估阿米洛利10-20 mg每日一次对诊室收缩压的影响(亚研究3)。
- 314例中269例参与至少一个亚研究:亚研究1为126例,亚研究2为226例,亚研究3为146例。
主要发现
- 螺内酯降低家庭收缩压的幅度可由醛固酮/肾素比值(r2=0·13,p<0·0001)和血浆肾素(r2=0·11,p=0·00024)预测。
- 42例血浆肾素浓度低(预设为血浆肾素最低三分位),其中31例血浆醛固酮浓度高于全部126例患者的均值250 pmol/L。
- 126例中31例(25%,95%CI 17-33)被认为醛固酮浓度不适当升高。
- 螺内酯使胸腔液体含量较基线降低6·8%(95%CI 4·0-8·8;p<0·0001),其他治疗无此变化。
- 阿米洛利10 mg每日一次使诊室收缩压降低20·4 mm Hg(95%CI 18·3-22·5),螺内酯25 mg每日一次降低18·3 mm Hg(95%CI 16·2-20·5);未记录到严重不良事件,双盲治疗结束后未系统记录不良症状;平均血浆钾浓度由安慰剂的4·02 mmol/L(95%CI 3·95-4·08)升至阿米洛利的4·50 mmol/L(95%CI 4·44-4·57)(p<0·0001)。
临床怎么用
- 作者认为难治性高血压常为盐潴留状态,最可能由醛固酮不适当分泌所致。
- 作者认为螺内酯通过阻断盐皮质激素受体克服盐潴留及高血压对治疗的抵抗。
- 作者认为阿米洛利似乎与螺内酯降压效果相当,为难治性高血压提供了替代治疗选择。
局限性
- 双盲治疗结束后未系统记录不良症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. METHODS: PATHWAY-2 was a randomised, double-blind crossover trial done at 14 UK primary and secondary care sites in 314 patients with resistant hypertension. Patients were given 12 weeks of once daily treatment with each of placebo, spironolactone 25-50 mg, bisoprolol 5-10 mg, and doxazosin 4-8 mg and the change in home systolic blood pressure was assessed as the primary outcome. In our three substudies, we assessed plasma aldosterone, renin, and aldosterone-to-renin ratio (ARR) as predictors of home systolic blood pressure, and estimated prevalence of primary aldosteronism (substudy 1); assessed the effects of each drug in terms of thoracic fluid index, cardiac index, stroke index, and systemic vascular resistance at seven sites with haemodynamic monitoring facilities (substudy 2); and assessed the effect of amiloride 10-20 mg once daily on clinic systolic blood pressure during an optional 6-12 week open-label runout phase (substudy 3). The PATHWAY-2 trial is registered with EudraCT, number 2008-007149-30, and ClinicalTrials.gov, number NCT02369081. FINDINGS: Of the 314 patients in PATHWAY-2, 269 participated in one or more of the three substudies: 126 in substudy 1, 226 in substudy 2, and 146 in substudy 3. Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024). 42 patients had low renin concentrations (predefined as the lowest tertile of plasma renin), of which 31 had a plasma aldosterone concentration greater than the mean value for all 126 patients (250 pmol/L). Thus, 31 (25% [95% CI 17-33]) of 126 patients were deemed to have inappropriately high aldosterone concentrations. Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; p<0·0001) with spironolactone, but not other treatments. Amiloride (10 mg once daily) reduced clinic systolic blood pressure by 20·4 mm Hg (95% CI 18·3-22·5), compared with a reduction of 18·3 mm Hg (16·2-20·5) with spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased from 4·02 mmol/L (95% CI 3·95-4·08) on placebo to 4·50 (4·44-4·57) on amiloride (p<0·0001). INTERPRETATION: Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to inappropriate aldosterone secretion. Mineralocorticoid receptor blockade by spironolactone overcomes the salt retention and resistance of hypertension to treatment. Amiloride seems to be as effective an antihypertensive as spironolactone, offering a substitute treatment for resistant hypertension. FUNDING: British Heart Foundation and UK National Institute for Health Research.
引用
- Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018. PMID: 29655877. doi:10.1016/S2213-8587(18)30071-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。